Apard T, Saint-Cast Y
Département de chirurgie osseuse, CHU d'Angers, 1, rue Larrey, 49033 Angers cedex, France.
Chir Main. 2007 Apr;26(2):88-94. doi: 10.1016/j.main.2007.03.005. Epub 2007 Apr 19.
The surgical gold standart treatment of the thumb osteoarthritis is the trapeziectomy with tendon interposition with ligament reconstruction. The trapeziometacarpal prosthesis is insufficiently assessed in literature.
Between 1994 and 2001, 43 trapeziometacarpal prosthesis Arpe were implanted by the same surgeon for isolated trapeziometacarpal degenerative osteoarthritis. The minimum follow-up is 5 years. 33 women and 2 men , average age 59,4-years, were operated after failure of conservative treatment. 7 patients were lost sight of (9 prosthesis) and 2 deaths (2 prosthesis). 26 other patients (32 prostheses) were examined by the author with an original revision questionnaire associated to the score of DASH.
7 revisions were necessary: 5 for loosening, 1 for premature dismemberment and 1 for recurrent partial dislocation. The survival of the prosthesis is 85% in 5 years. In the group of 25 prosthesis still implanted, there is no radiological sign of loosening, but in some cases a development of medial ossification. The average DASH score is 27,4/100. All the patients of this group are satisfied or very satisfied.
The prosthesis Arpe is an effective option in this series for the treatment of the degenerative trapeziometacarpal arthritis but its radioclinical control is necessary for the first year.
拇指骨关节炎的外科金标准治疗方法是带肌腱植入和韧带重建的大多角骨切除术。大多角骨-掌骨假体在文献中的评估尚不充分。
1994年至2001年间,同一位外科医生为孤立性大多角骨-掌骨退行性骨关节炎植入了43枚Arpe大多角骨-掌骨假体。最短随访时间为5年。33名女性和2名男性,平均年龄59.4岁,在保守治疗失败后接受了手术。7名患者失访(9枚假体),2名患者死亡(2枚假体)。作者用一份与DASH评分相关的原始修订问卷对其他26名患者(32枚假体)进行了检查。
需要进行7次翻修:5次因松动,1次因过早脱位,1次因复发性部分脱位。假体5年生存率为85%。在仍植入的25枚假体组中,没有松动的放射学迹象,但在某些情况下有内侧骨化的发展。平均DASH评分为27.4/100。该组所有患者均满意或非常满意。
在本系列中,Arpe假体是治疗退行性大多角骨-掌骨关节炎的一种有效选择,但在第一年需要进行放射临床监测。